Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00979667
Other study ID # CCT2009-CS-6
Secondary ID
Status Terminated
Phase Phase 3
First received September 17, 2009
Last updated April 8, 2011
Start date October 2009
Est. completion date October 2010

Study information

Verified date May 2010
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Department of Health
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.


Description:

The outbreak of respiratory illnesses in Mexico that began in March 2009 was caused by a swine origin influenza A (H1N1) virus (S-OIV) that had not been recognized previously in pigs or humans. As of 17 May 2009, 39 countries have officially reported 8480 cases of influenza A (H1N1) infection.

The H1N1 influenza A virus appears sensitive to oseltamivir and zanamivir in vitro, but resistant to amantadine and rimantadine. This study is to test the oseltamivir, zanamivir and placebo arms as the first line treatment for human swine influenza infection. Through the study, the investigators may have better understanding about the clinical and, biochemical, virological profiles of oseltamivir/zanamivir on the H1N1 virus, and optimizing the treatment strategy among the Chinese population.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date October 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patients 18 years or older with body weight >40kg

- Written informed consent

- Presented within 48 hours of onset of influenza-like illness

- Presumptive diagnosis of H1N1 satisfying the following clinical and laboratory criteria:

- Clinical criteria

- Fever >38 oC (Infrared Forehead Thermometer will be used to measure the Temporal Artery Temperature under the skin) AND

- At least one upper respiratory tract infection (cough, running nose, sore throat)

- Laboratory criteria Positive rapid test result for influenza A (by Influenza Rapid Diagnostic test) within 48 hours of onset of flu-like symptoms

Exclusion Criteria:

- Age below 18 years

- Persons who lack the ability to care for themselves

- Patient with critical condition or already developed severe respiratory distress with hypoxaemia on presentation

- Pregnancy or lactation

- Coexisting liver disease

- Coexisting cardiovascular disease except stable hypertension without complication

- Coexisting chronic pulmonary disease

- Coexisting immuno-compromised medical conditions or on concurrent immunosuppressive therapies

- Renal failure

- Terminal malignancies or terminal end-organ failure with an estimated life-expectancy of less than 3 months

- Known intolerance to oseltamivir or zanamivir

- Known history of significant neurological disorders that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration or those

- Subjects who have received oseltamivir as prophylaxis for H1N1 infection

- Subjects who have received any investigational drug within 1 month prior to study entry

- Subjects with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Oseltamivir
75 mg twice daily for 5 days
Zanamivir
10 mg twice daily for 5 days
Placebo of Oseltamivir
twice daily for 5 days

Locations

Country Name City State
China Shau Kei Wan Jockey Club Clinic Hong Kong Hong Kong
Hong Kong Fanling Family Medicine Centre Hong Kong
Hong Kong Sai Ying Pun Jockey Club General Outpatient Clinic Hong Kong

Sponsors (3)

Lead Sponsor Collaborator
Chinese University of Hong Kong Food and Health Bureau, Hong Kong, Hospital Authority

Countries where clinical trial is conducted

China,  Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to symptoms resolution as reported by the patient one week No
Secondary Treatment failure including hospitalization due to disease worsening. one week Yes
Secondary Viral load one week Yes
Secondary Severity of disease as measured by the patient diary and quality of life using SF12v2. one week Yes
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A